<DOC>
	<DOCNO>NCT01739647</DOCNO>
	<brief_summary>This single dose study healthy male female ( non-child bearing potential ) volunteer , assess safety , effect body , blood urine drug level AZD3293 . AZD3293 develop treatment Alzheimer 's Disease</brief_summary>
	<brief_title>A Single Dose Study Assess Safety , Effects , Blood Urine Drug Levels AZD3293 Healthy Subjects</brief_title>
	<detailed_description>A Phase I , Randomized , Double-Blind , Placebo-Controlled , Single Ascending Dose Study Assess Safety , Tolerability , Pharmacokinetics Effect Biomarkers AZD3293 Including Open-Label Food Effect Group Healthy Male Non-Fertile Female Volunteers</detailed_description>
	<criteria>Healthy male female ( nonchildbearing potential ) subject Body mass index ( BMI ) 19 30 kg/m2 weigh least 50 kg 100 kg History presence psychiatric disease/condition , GI , renal , hepatic , cardiovascular , psychiatric , retinal disease disorder History neurological disease , include seizure , recent memory impairment , clinically significant head injury History use antipsychotic drug , chronic use antidepressant anxiolytic drug Frequent use ( 2 day per week last 12 week ) tobacco nicotine product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>AZD3293</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Elderly volunteer</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Single Ascending Dose Study</keyword>
</DOC>